In a nutshell, this finding elucidated a plausible mechanism responsible for the constitutive activation of AKT-mTOR signaling during tumor promotion of OC, supporting the notion that SNHG15 might be a novel target for clinical treatment for cancer patients. This evidence concerns the gene AKT1 and cancer.